Maddi Hebebrand, MC, Associate Editor

Alpha-9 Oncology's A9-3408 trial targets MC1R in advanced melanoma, offering a novel radiotherapeutic approach beyond traditional treatments.

Cosmo Pharmaceuticals reveals promising phase 3 results for clascoterone 5% solution, showing significant hair growth improvement in alopecia.

Tori Spelling and Stella McDermott share their journey with eczema, promoting the Free to Be Me campaign and discussing innovative treatments like roflumilast.

Discover how a proprietary extract from saw palmetto promotes hair growth and reduces thinning in adults, offering a safe alternative to traditional treatments.

The study provides new evidence beyond previously established associations with breast, ovarian, and uterine cancers.

Navigator Medicines advances NAV-240, a promising bispecific antibody for HS, targeting dual pathways for enhanced treatment efficacy.

However, over half of the patients reported experiencing psychological symptoms such as mood changes and depression during treatment.

Participants agreed that HS is rarely controlled with monotherapy and often requires coordinated multimodal care.

Support vital dermatology organizations this Giving Tuesday and beyond to enhance patient care, drive research, and foster community.

While individual fatty acids in tallow have known biological effects, their combined impact in whole tallow remains uncertain.

Bayesian network meta-analysis and MAIC consistently favored deuruxolitinib over baricitinib and ritlecitinib for SALT ≤10 and ≤20 endpoints.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Explore the top headlines of the month, including insights on regulatory updates, expert pearls, and more.

Hair growth, density, and aging patterns differ across populations, influencing the presentation and management of hair disorders like alopecia areata.

Dermatology Times is recapping our exclusive expert interviews from the month of November.

Michael Lewitt, MD, reassures patients that topical ruxolitinib shows minimal systemic absorption despite sharing a mechanism with oral JAK inhibitors.

High-dose topical delgocitinib significantly outperformed oral alitretinoin in reducing HECSI severity at both 12 and 16 weeks.

Discover the potential of INF904, a groundbreaking oral therapy targeting C5aR for hidradenitis suppurativa and chronic spontaneous urticaria, promising new treatment options.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Explore the latest advancements and expert insights from ISDS 2025 held in New York, New York.

Massimo Gadina, PhD, underscored the need for genetics-guided patient selection to improve treatment specificity in inflammatory skin diseases.

Michael Lewitt, MD, emphasizes adherence to twice-daily application as the primary determinant of clinical success.

Dupilumab clears AD clinically and histologically, but deep immune profiling shows disease-memory T cells persist in the skin.

New research reveals ritlecitinib's potential to reverse scarring alopecias by targeting inflammation, offering hope for hair regrowth in autoimmune disorders.

Discover the latest insights on hidradenitis suppurativa treatment, emerging therapies, and the importance of compassionate care for patients.

Benjamin Ungar, MD, shares groundbreaking insights on seborrheic dermatitis and emerging treatments in dermatology at ISDS 2025.

Using multiple treatment modalities often achieves superior repigmentation compared with monotherapy, according to Michael Lewitt, MD.

Experts discuss hair loss challenges and treatments for skin of color, highlighting the importance of early intervention and accurate diagnosis.